Aurobindo Reprimanded By SEBI Over US FDA Warning Disclosure
‘Very Limited And Restricted Information’ Revealed By Indian Firm Deemed ‘Insufficient’
Executive Summary
The Securities and Exchange Board of India has warned Aurobindo that it did not disclose sufficient information about a US FDA warning letter that it received in connection with its Unit 1 API facility in Hyderabad early this year.
You may also be interested in...
AAM Laments Price Negotiation Legislation Passing US Senate
The AAM has criticized the passage of the US Inflation Reduction Act though the country’s Senate, claiming that the legislation’s “flawed framework for government price setting” will chill generic and biosimilar development and will reduce patient access.
Mayne And Mithra Obtain Long-Awaited NuvaRing Nod From FDA
Following a trio of complete response letters received since late 2018, Mayne Pharma and partner Mithra Pharmaceuticals have finally obtained US FDA approval for a generic version of Organon’s NuvaRing vaginal hormonal contraceptive ring.
Cutting Through The Confusion On US Biosimilar Interchangeability
Amid ongoing confusion around the US interchangeability designation for biosimilars, Joseph Park and Gillian Woollett of Samsung Bioepis talk to Generics Bulletin about the risks of misinformation, the importance of educational efforts, and how language is shaping certain misunderstandings around biosimilars.